Last updated on November 2019

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Brief description of study

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

Clinical Study Identifier: NCT03915964

Find a site near you

Start Over

Chris Hani Baragwanath Hospital

Soweto, South Africa
  Connect »